-k.k.

-k.k.

-k.k.

PERIOD TARGET COMPANY

ACQUIRER DEAL VALUE

FEB ’07 Hutch-Essar Vodafone 13.1

JUN’08 Ranbaxy Lab Daiichi Sankyo 4.6

APR’06 Flextronics KRR & Vo LP 0.9

JAN’06 Ambuja Cem Holcim 0.6

AUG’06 Matrix Lab Mylan Inc 0.5

Deal Value in billion Dollar

-k.k.

PERIOD TARGET COMPANY

ACQUIRER DEAL VALUE

FEB ’07 Hutch-Essar Vodafone 13.1

JUN’08 Ranbaxy Lab Daiichi Sankyo 4.6

APR’06 Flextronics KRR & Vo LP 0.9

JAN’06 Ambuja Cem Holcim 0.6

AUG’06 Matrix Lab Mylan Inc 0.5

-k.k.

Ranbaxy- Daiichi Sankyo Deal

HISTORY

How Ranbaxy & Daiichi fell in Love

WHY SELL OUT???HOW THE DEAL

WORKS

IMPACT ON INDIAN PHARMA SECTOR

WHAT AHEAD FOR THE COMPANY

Thank You

HISTORY

Sankyo

Benicar(olmesartan medoxomil)Mevalotin (pravastatin)Loxonin (loxoprofen)Olmetec (olmesartan)CaptoprilZantac (ranitidine)WelChol (colesevelam HCl)

Daiichi Pharmaceutical

Cravit (levofloxacin)Evoxac (cevimeline)

FloxinOtic (ofloxacin)

-k.k.

Ranbaxy- Daiichi Sankyo Deal

HISTORY

How Ranbaxy & Daiichi fell in Love

WHY SELL OUT???HOW THE DEAL

WORKS

IMPACT ON INDIAN PHARMA SECTOR

WHAT AHEAD FOR THE COMPANY

Thank You

How Ranbaxy and Daiichi fell in Love

-k.k.

Ranbaxy- Daiichi Sankyo Deal

HISTORY

How Ranbaxy & Daiichi fell in Love

WHY SELL OUT???HOW THE DEAL

WORKS

IMPACT ON INDIAN PHARMA SECTOR

WHAT AHEAD FOR THE COMPANY

Thank You

WHY SELL ???OUT???

-k.k.

Ranbaxy- Daiichi Sankyo Deal

HISTORY

How Ranbaxy & Daiichi fell in Love

WHY SELL OUT???HOW THE DEAL

WORKS

IMPACT ON INDIAN PHARMA SECTOR

WHAT AHEAD FOR THE COMPANY

Thank you

-k.k.

HOW THE DEAL WORKS

Daiichi sets to acquire a controlling stake--- 51-62% --- in Ranbaxy for $3.4-4.6 billion.

Singh family to sell entire stake 34.8% for Rs 10,000 crore($2.4 b) at Rs 737 per Share.

Japanese company to pick up another 9.4% in Ranbaxy through preferential allotment.

Daiichi will have to make an open offer to acquire 20% more from other share holders.

Japanese company can acquire another 4.9% through preferential issue of share warrants.

Ranbaxy to get $1 b via preferential allotment. Funds to be used to retire debt.

-k.k

Particulars Number of SharesAcquisition of Shares under Open Offer

92,519,126

Allotment of Shares on Preferential basis

46,258,063

Acquisition of Shares from the Singh family

129,934,134

The Land Mark Deal Completed On 7th Nov, 2008

-k.k.

Ranbaxy- Daiichi Sankyo Deal

HISTORY

How Ranbaxy & Daiichi fell in Love

WHY SELL OUT???HOW THE DEAL

WORKS

IMPACT ON INDIAN PHARMA SECTOR

WHAT AHEAD FOR THE COMPANY

Thank You

-k.k.

IMPACT ON INDIAN PHARMA INDUSTRY

Deal may Prompt other Indian promoters to divest their stake at the right place and at right time, instead of clinching on for the emotional attachment.

Commercially it is an awesome deal but Ranbaxy was a hero for those who has Global aspiration. A huge positive for Ranbaxy but a negative for Indian pharma.

Acquisition may dampen the motivation of other aspirants who want to emulate Ranbaxy’s success in the global pharma industry.

-k.k.

Ranbaxy- Daiichi Sankyo Deal

HISTORY

How Ranbaxy & Daiichi fell in Love

WHY SELL OUT???HOW THE DEAL

WORKS

IMPACT ON INDIAN PHARMA SECTOR

WHAT AHEAD FOR THE COMPANY

Thank You

-k.k.

-k.k.

-k.k.

Ranbaxy- Daiichi Sankyo Deal

HISTORY

How Ranbaxy & Daiichi fell in Love

WHY SELL OUT???HOW THE DEAL

WORKS

IMPACT ON INDIAN PHARMA SECTOR

WHAT AHEAD FOR THE COMPANY

Thank You

-k.k